Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation Between Prognosis and Disease Susceptibility Loci

Overview

Journal Inflamm Intest Dis

Date 2021 Nov 1

PMID 34722645

Authors

Kasumi Hishinuma

Rintaro Moroi

Daisuke Okamoto

Yusuke Shimoyama

Masatake Kuroha

Hisashi Shiga

Yoichi Kakuta

Yoshitaka Kinouchi

Atsushi Masamune

Affiliations

Soon will be listed here.

Abstract

Background: New therapeutic agents, including biologics and small-molecule drugs, are widely used to treat ulcerative colitis (UC). This study evaluates long-term prognosis in Japanese patients treated with these agents and the association between prognosis and genetic susceptibility to UC.

Methods: We evaluated surgery-free rates using the Kaplan-Meier method in the total cohort and in patients treated with prednisolone and new therapeutic agents. Multivariate analysis was performed to identify clinical factors affecting surgical rates using Cox's proportional hazard model. The rate of use of new therapeutic agents was compared using the Kaplan-Meier method, and multivariate analysis was conducted to investigate the correlation between the single-nucleotide polymorphism (SNP) rs117506082 and long-term prognosis.

Results: Surgery-free survival decreased over time. There was no significant difference in this parameter between patients who were administered prednisolone and those who were administered new therapeutic agents. Poor response to prednisolone and treatment without topical 5-aminosalicylic acid were poor prognostic factors. Shorter time from diagnosis to initiation of treatment with new therapeutic agents was a risk factor for colectomy. The AA genotype of SNP rs117506082 was associated with a shorter time to surgery and increased use of new therapeutic agents.

Conclusions: The use of new therapeutic agents might improve long-term prognosis in patients with more severe UC. Previously identified genetic risk factors were not significantly associated with a higher rate of colectomy.

References

Andrew R, Messaris E . Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new?. World J Gastrointest Surg. 2016; 8(9):598-605. PMC: 5037332. DOI: 10.4240/wjgs.v8.i9.598. View

Sandborn W, Su C, Sands B, DHaens G, Vermeire S, Schreiber S . Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017; 376(18):1723-1736. DOI: 10.1056/NEJMoa1606910. View

Sicilia B, Vicente R, Arroyo M, Arribas F, Gomollon F . [Ulcerative pancolitis predicts the need for colectomy: study of an incident cohort of patients with ulcerative colitis in Aragón (Spain)]. Gastroenterol Hepatol. 2005; 28(2):55-9. DOI: 10.1157/13070700. View

Lee H, Jung E, Lee J, Hong S, Kim T, Kim W . Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Hepatogastroenterology. 2012; 59(117):1415-20. DOI: 10.5754/hge10680. View

Rungoe C, Langholz E, Andersson M, Basit S, Nielsen N, Wohlfahrt J . Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2013; 63(10):1607-16. DOI: 10.1136/gutjnl-2013-305607. View

Uchino M, Ikeuchi H, Hata K, Okada S, Ishihara S, Morimoto K . Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study. Surg Today. 2019; 49(12):1066-1073. DOI: 10.1007/s00595-019-01845-2. View

Rutgeerts P, Sandborn W, Feagan B, Reinisch W, Olson A, Johanns J . Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-76. DOI: 10.1056/NEJMoa050516. View

TRUELOVE S, Witts L . Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955; 2(4947):1041-8. PMC: 1981500. DOI: 10.1136/bmj.2.4947.1041. View

Kawai Y, Mimori T, Kojima K, Nariai N, Danjoh I, Saito R . Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals. J Hum Genet. 2015; 60(10):581-7. PMC: 4635170. DOI: 10.1038/jhg.2015.68. View

10.

Alkim C, Alkim H, Dagli U, Parlak E, Ulker A, Sahin B . Extension of ulcerative colitis. Turk J Gastroenterol. 2011; 22(4):382-7. DOI: 10.4318/tjg.2011.0241. View

11.

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

12.

Sandborn W, Van Assche G, Reinisch W, Colombel J, DHaens G, Wolf D . Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2011; 142(2):257-65.e1-3. DOI: 10.1053/j.gastro.2011.10.032. View

13.

Feuerstein J, Isaacs K, Schneider Y, Siddique S, Falck-Ytter Y, Singh S . AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020; 158(5):1450-1461. PMC: 7175923. DOI: 10.1053/j.gastro.2020.01.006. View

14.

Ko C, Singh S, Feuerstein J, Falck-Ytter C, Falck-Ytter Y, Cross R . AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2018; 156(3):748-764. PMC: 6858922. DOI: 10.1053/j.gastro.2018.12.009. View

15.

Rizzo G, Pugliese D, Armuzzi A, Coco C . Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?. World J Gastroenterol. 2014; 20(17):4839-45. PMC: 4009515. DOI: 10.3748/wjg.v20.i17.4839. View

16.

Sandborn W, Rutgeerts P, Feagan B, Reinisch W, Olson A, Johanns J . Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009; 137(4):1250-60. DOI: 10.1053/j.gastro.2009.06.061. View

17.

Bressler B, Marshall J, Bernstein C, Bitton A, Jones J, Leontiadis G . Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015; 148(5):1035-1058.e3. DOI: 10.1053/j.gastro.2015.03.001. View

18.

Liu J, van Sommeren S, Huang H, Ng S, Alberts R, Takahashi A . Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015; 47(9):979-986. PMC: 4881818. DOI: 10.1038/ng.3359. View

19.

Fellermann K, Tanko Z, Herrlinger K, Witthoeft T, Homann N, Bruening A . Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002; 8(5):317-24. DOI: 10.1097/00054725-200209000-00002. View

20.

Baumgart D, Carding S . Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369(9573):1627-40. DOI: 10.1016/S0140-6736(07)60750-8. View